Skip to main content

Table 1 Baseline characteristics for patients undergoing valve surgery for IE by age groups

From: Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery

  All < 60 years 60–75 years ≥75 years  
Number 1767 735 766 266  
Age, median (IQR) 63 [52.7, 71.6] 50 [41.4, 55.6] 67.7 [63.8, 71.3] 78.2 [76.3, 80.3] < 0.001
Female, N (%) 471 (26.7) 177 (24.1) 198 (25.8) 96 (36.1) 0.0006
Medical history prior to IE admission, N (%)
 AMI 102 (5.8) 26 (3.5) 52 (6.8) 24 (9.0) 0.001
 Heart failure 220 (12.5) 56 (7.6) 116 (15.1) 48 (18.0) < 0.001
 Afib 241 (13.6) 35 (4.8) 142 (18.5) 64 (24.1) < 0.001
 Mitral valve disease 165 (9.3) 52 (7.1) 86 (11.2) 27 (10.2) 0.02
 Aortic valve disease 455 (25.7) 107 (14.6) 227 (29.6) 121 (45.5) < 0.001
 CIED 71 (4.0) 16 (2.2) 34 (4.4) 21 (7.9) < 0.001
 Prosthetic heart valve 228 (12.9) 51 (6.9) 104 (13.6) 73 (27.4) < 0.001
 Renal disease 123 (7.0) 57 (7.8) 53 (6.9) 13 (4.9) 0.29
 Dialysis 28 (1.6) 12 (1.6) 14 (1.8) < 4 0.48
 Peripheral vascular disease 149 (8.4) 34 (4.6) 78 (10.2) 37 (13.9) < 0.001
 Cerebrovascular disease 158 (8.9) 38 (5.2) 80 (10.4) 40 (15.0) < 0.001
 Cancer 191 (10.8) 44 (6.0) 104 (13.6) 43 (16.2) < 0.001
 COPD 128 (7.2) 21 (2.9) 77 (10.1) 30 (11.3) < 0.001
 Liver disease 57 (3.2) 28 (3.8) 24 (3.1) 5 (1.9) 0.31
 Diabetes 182 (10.3) 49 (6.7) 95 (13.1) 34 (12.8) < 0.001
Medication six months prior to IE admission, N (%)
 Diuretics 543 (30.7) 120 (16.3) 301 (39.3) 122 (45.9) < 0.001
 Beta blockade 409 (23.1) 100 (13.6) 223 (29.1) 86 (32.3) < 0.001
 RAS inhibition 547 (31.0) 133 (18.1) 305 (39.8) 109 (41.0) < 0.001
 Lipid lowering medication 428 (24.2) 82 (11.2) 243 (31.7) 103 (38.7) < 0.001
 Corticosteroids 138 (7.8) 42 (5.7) 69 (9.5) 26 (9.8) 0.02
 Aspirin 367 (20.8) 70 (9.5) 175 (24.1) 104 (39.1) < 0.001
 Anticoagulants 298 (16.9) 74 (10.1) 147 (20.2) 61 (22.9) < 0.001
 Antibiotics 899 (50.9) 359 (48.8) 374 (51.4) 149 (56.0) 0.13
  1. IE infective endocarditis, IQR interquartile range, 25th and 75th percentile, AMI acute myocardial infarction, Afib atril fibrillation/flutter, CIED cardiac implantable electronic device, COPD chronic obstructive pulmonary disease, RAS renin-angiotensin system
  2. The percentages of the qualitative variables are shown in parentheses